AUSTIN, Texas–(BUSINESS WIRE)–Two U.S. patents provide protection for PTM-101 in pancreatic cancer and support expansion of Sagittari™ platform across multiple tumor indications.

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.